Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Peter Siostrzonek et al.|The Lancet|2017Cited by 1.3k
European Society of Cardiology: cardiovascular disease statistics 2021Adam Timmis, Alen Džubur, Panos Vardas et al.|European Heart Journal|2021Cited by 1.1k
European Society of Cardiology: Cardiovascular Disease Statistics 2019Adam Timmis, Hera Heracleous Moustra, Nick Townsend et al.|European Heart Journal|2019Cited by 1k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881